Biopharmx Corp (NYSEAMERICAN:BPMX) shares were up 10.5% on Monday . The company traded as high as $0.19 and last traded at $0.17. Approximately 4,767,908 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 11,409,313 shares. The stock had previously closed at $0.19.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.50 price target on shares of Biopharmx in a research report on Friday, December 8th.

The firm has a market cap of $21.46, a price-to-earnings ratio of -0.62 and a beta of 1.40.

Biopharmx (NYSEAMERICAN:BPMX) last announced its quarterly earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.05).

In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of Biopharmx stock in a transaction on Friday, November 24th. The shares were bought at an average price of $0.15 per share, with a total value of $49,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

WARNING: “Biopharmx (BPMX) Trading Up -10.5%” was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with's FREE daily email newsletter.